Public-Private Partnerships Like IMI Crucial to Industry's Future, Argue Leaders

Public-private partnerships like Europe's Innovative Medicines Initiative, the EU’s mechanism that promotes new treatment R&D, are crucial to the industry's future, according to Paul Stoffels, Chairman global R&D pharmaceuticals at Johnson & Johnson.

More from Archive

More from Pink Sheet